Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies

New license agreement expands Genprex’s oncology franchise   Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including:   Pembrolizumab (Merck’s largest selling drug Keytruda) Nivolumab (Bristol-Myers Squibb’s Opdivo) Ipilimumab (Bristol-Myers Squibb’s Yervoy)   AUSTIN, Texas — (May 5, 2020) — Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage […]

Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Austin, TX & Cambridge, MA – Feburary 5, 2020-  Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex […]